• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Cardlytics Inc.

    1/23/25 4:14:09 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology
    Get the next $CDLX alert in real time by email
    S-8 1 cdlx_2025evergreenpoolincr.htm S-8 Document
    As filed with the Securities and Exchange Commission on January 23, 2025
    Registration No. 333-
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549
    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933
    cardlytics_logoa12a.jpg
    CARDLYTICS, INC.
    (Exact Name of Registrant as Specified in its Charter)
    675 Ponce de Leon Avenue NE, Suite 4100
    DelawareAtlanta, Georgia 3030826-3039436
    (State or other jurisdiction of
    incorporation or organization)
    (Address of principal executive offices) (Zip code)(I.R.S. Employer
    Identification No.)
    2018 Equity Incentive Plan
    2018 Employee Stock Purchase Plan
    (Full title of the plan)
    Amit Gupta
    Cardlytics, Inc.
    675 Ponce de Leon Avenue NE, Suite 4100
    Atlanta, Georgia 30308
    (Name and address of agent for service)
    (888) 798-5802
    (Telephone number, including area code, of agent for service)
    Copies to:
    Mark Ballantyne
    Trey Reilly
    Cooley LLP
    One Freedom Square
    Reston Town Center
    11951 Freedom Drive
    Reston, VA 20190
    (703) 456-8000
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
    Large accelerated filer ☐  Accelerated filer ☒
    Non-accelerated filer ☐  Smaller reporting company ☐
      Emerging growth company☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act ☐




    EXPLANATORY NOTE
    Pursuant to General Instruction E of Form S-8, Cardlytics, Inc. (the “Registrant”) is filing this Registration Statement with the Securities and Exchange Commission (the “Commission”) to register 2,562,851 additional shares of its common stock under the 2018 Equity Incentive Plan (the “2018 Plan”) and 500,000 additional shares of its common stock under the 2018 Employee Stock Purchase Plan (the “2018 ESPP”), pursuant to the provisions of the 2018 Plan and the 2018 ESPP providing for an automatic increase in the number of shares of common stock reserved and available for issuance under the 2018 Plan and the 2018 ESPP, as applicable, on January 1, 2025. In accordance with the instructional note to Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of the Form S-8 has been omitted from this Registration Statement.
    PART II
    ITEM 3.    INCORPORATION OF DOCUMENTS BY REFERENCE
    The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:
    (a) The contents of the earlier registration statements related to the 2018 Plan and the 2018 ESPP, previously filed with the Commission on February 9, 2018 (File No. 333-222965), May 21, 2019 (File No. 333-231640), March 3, 2020 (File No. 333-236869), March 1, 2021 (File No. 333-253675), March 1, 2022 (File No. 333-263143), January 23, 2023 (File No. 333-269361) and January 29, 2024 (File No. 333-276737) are incorporated herein by reference and made a part of this Registration Statement.
    (b) The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Commission on March 14, 2024.
    (c) The information specifically incorporated by reference into the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2023 from the Registrant’s definitive proxy statement on Schedule 14A, as filed with the Commission on April 12, 2024.
    (d) The Registrant’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2024, June 30, 2024 and September 30, 2024, which were filed with the Commission on May 8, 2024, August 7, 2024 and November 6, 2024, respectively.
    (e) The Registrant’s Current Reports on Form 8-K filed with the Commission on January 2, 2024 (with respect to Item 5.02 only), January 29, 2024 (with respect to Item 1.01 only), March 14, 2024, March 18, 2024, April 1, 2024, April 9, 2024 (with respect to Item 5.02 only), May 23, 2024, August 7, 2024 (with respect to Item 5.02 only) (as amended on Form 8-K/A on August 21, 2024), October 3, 2024 and November 4, 2024.
    (f) The description of the Registrant’s Common Stock which is contained in the Registrant’s Registration Statement on Form 8-A filed on February 6, 2018 (File No. 001-38386) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including any amendment or report filed for the purpose of updating such description, including Exhibit 4.3 to the Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the Commission on March 3, 2020.
    (g) All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.



    ITEM 8.    EXHIBITS
    Exhibit NumberDescription
    4.1(1)
    Amended and Restated Certificate of Incorporation of the Registrant
    4.2(2)
    Amended and Restated Bylaws of the Registrant
    4.3(3)
    2018 Equity Incentive Plan and Forms of Stock Option Agreement, Notice of Exercise, Stock Option Grant Notice. Restricted Stock Unit Notice and Restricted Stock Agreement thereunder.
    4.4(4)
    2018 Employee Stock Purchase Plan
    4.5(5)
    Specimen stock certificate evidencing shares of Common Stock
    5.1(6)
    Opinion of Cooley LLP
    23.1(6)
    Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm
    23.2(6)
    Consent of Cooley LLP (included in Exhibit 5.1)
    24.1(6)
    Power of Attorney (included on the signature page of this Form S-8)
    107(6)
    Filing Fee Table
    (1)Previously filed as Exhibit 3.2 to the Registrant’s Registration Statement on Form S-1 (File No. 333-222531), filed with the Commission on January 12, 2018, and incorporated by reference herein.
    (2)Previously filed as Exhibit 3.4 to the Registrant’s Registration Statement on Form S-1 (File No. 333-222531), filed with the Commission on January 12, 2018, and incorporated by reference herein.
    (3)Previously filed as Exhibit 10.2 to Amendment No. 1 to the Registrant’s Registration Statement on Form S-1 (File No. 333-222531), filed with the Commission on January 29, 2018, and incorporated by reference herein.
    (4)Previously filed as Exhibit 10.3 to Amendment No. 1 to the Registrant’s Registration Statement on Form S-1 (File No. 333-222531), filed with the Commission on January 29, 2018, and incorporated by reference herein.
    (5)Previously filed as Exhibit 4.1 to Amendment No. 1 to the Registrant’s Registration Statement on Form S-1 (File No. 333-222531), filed with the Commission on January 29, 2018, and incorporated by reference herein.
    (6)Filed herewith.
    SIGNATURES
    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S‑8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Atlanta, State of Georgia, on January 23, 2025.
    CARDLYTICS, INC.
    By:/s/ Amit Gupta
    Amit Gupta
    Chief Executive Officer

    POWER OF ATTORNEY
    Know All Persons By These Presents, that each person whose signature appears below constitutes and appoints Amit Gupta, Nick Lynton and Alexis DeSieno, and each or any one of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.
    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.



    SignatureTitleDate
    /s/ Amit GuptaChief Executive Officer and DirectorJanuary 23, 2025
    Amit Gupta(Principal Executive Officer)
    /s/ Alexis DeSienoChief Financial OfficerJanuary 23, 2025
    Alexis DeSieno(Principal Financial and Accounting Officer)
    /s/ John Klinck
    Chairperson
    January 23, 2025
    John Klinck
    /s/ Jon FrancisDirectorJanuary 23, 2025
    Jon Francis
    /s/ Andre FernandezDirectorJanuary 23, 2025
    Andre Fernandez
    /s/ Srishti GuptaDirectorJanuary 23, 2025
    Srishti Gupta
    /s/ Scott HillDirectorJanuary 23, 2025
    Scott Hill
    /s/ Liane HornseyDirectorJanuary 23, 2025
    Liane Hornsey
    /s/ Alex MishurovDirectorJanuary 23, 2025
    Alex Mishurov


    Get the next $CDLX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CDLX

    DatePrice TargetRatingAnalyst
    10/11/2024$4.00In-line
    Evercore ISI
    8/16/2024$5.00Outperform → Market Perform
    Northland Capital
    8/15/2024$4.00 → $3.50Neutral → Underperform
    BofA Securities
    8/8/2024Buy → Hold
    Craig Hallum
    8/8/2024Buy → Hold
    Needham
    8/8/2024$18.00 → $5.00Buy → Hold
    Lake Street
    6/20/2024$11.00Neutral
    BofA Securities
    6/18/2024$14.00Outperform
    Northland Capital
    More analyst ratings

    $CDLX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PAR Technology to Acquire Bridg, Bringing Loyalty and Non‑Loyalty Data Together for Smarter Retail and Restaurant Activation

    Acquisition will accelerate PAR's roadmap for consumer data, loyalty, and media innovation PAR Technology Corporation (NYSE:PAR), a leading global foodservice technology provider, today announced that it has agreed to acquire the identity resolution and shopper intelligence platform Bridg, a division of Cardlytics, Inc. (NASDAQ Global Market: CDLX). The transaction is structured as an acquisition of substantially all Bridg assets. The purchase price is $27.5 million, subject to purchase price adjustments with a maximum total purchase price of $30.0 million, and is payable in shares of PAR Technology common stock. PAR Technology will also assume certain liabilities associated with the acqu

    1/26/26 8:02:00 AM ET
    $CDLX
    $PAR
    Computer Software: Programming Data Processing
    Technology
    Office Equipment/Supplies/Services
    Miscellaneous

    Cardlytics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    Cardlytics, Inc. (NASDAQ:CDLX) today announced that on January 12, 2026, the Compensation Committee of Cardlytics' Board of Directors granted an aggregate of 1,000,000 restricted stock units of Cardlytics to its newly appointed Chief Financial Officer, David Evans. The restricted stock units were granted as a material inducement to employment with Cardlytics in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Cardlytics, Inc. 2022 Inducement Plan (the "2022 Inducement Plan"). Half of the restricted stock units underlying the award shall vest on February 1, 2027, and the remaining 50% shall vest quarterly over the subsequent 12 months, subject to Evans' continuous

    1/16/26 4:05:00 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Cardlytics Appoints Company Alumnus David Evans as Chief Financial Officer

    Cardlytics Inc. (NASDAQ:CDLX) today announced the appointment of David Evans as its new Chief Financial Officer, effective January 12, 2026. Evans is returning to Cardlytics, having previously held several executive roles including Chief Financial Officer and Chief Administrative Officer. As the returning Chief Financial Officer, Evans will oversee Cardlytics' finance, accounting, and investor relations functions as the company continues to execute against its longer-term growth vision. Evans rejoins Cardlytics after his initial tenure from 2014 to 2020, during which he helped guide the company through its earlier years of growth and a successful IPO in 2018. Evans is a seasoned executive

    12/18/25 8:10:00 AM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    $CDLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Evans David Thomas claimed ownership of 117,930 shares (SEC Form 3)

    3 - Cardlytics, Inc. (0001666071) (Issuer)

    1/16/26 4:51:29 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    SEC Form 4 filed by Chief Financial Officer Evans David Thomas

    4 - Cardlytics, Inc. (0001666071) (Issuer)

    1/16/26 4:46:07 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Chief Legal & Privacy Officer Lynton Nicholas Hollmeyer converted options into 12,788 shares and sold $7,316 worth of shares (6,253 units at $1.17), increasing direct ownership by 6% to 122,862 units (SEC Form 4)

    4 - Cardlytics, Inc. (0001666071) (Issuer)

    1/5/26 6:56:15 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    $CDLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $CDLX
    SEC Filings

    View All

    $CDLX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Evercore ISI initiated coverage on Cardlytics with a new price target

    Evercore ISI initiated coverage of Cardlytics with a rating of In-line and set a new price target of $4.00

    10/11/24 8:36:58 AM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Cardlytics downgraded by Northland Capital with a new price target

    Northland Capital downgraded Cardlytics from Outperform to Market Perform and set a new price target of $5.00

    8/16/24 8:54:02 AM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Cardlytics downgraded by BofA Securities with a new price target

    BofA Securities downgraded Cardlytics from Neutral to Underperform and set a new price target of $3.50 from $4.00 previously

    8/15/24 7:18:52 AM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Cardlytics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - Cardlytics, Inc. (0001666071) (Filer)

    1/26/26 8:00:34 AM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    SEC Form 144 filed by Cardlytics Inc.

    144 - Cardlytics, Inc. (0001666071) (Subject)

    1/5/26 4:23:23 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Cardlytics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Cardlytics, Inc. (0001666071) (Filer)

    12/18/25 8:00:14 AM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Director Hill Scott A bought $143,200 worth of shares (40,000 units at $3.58) (SEC Form 4)

    4 - Cardlytics, Inc. (0001666071) (Issuer)

    8/12/24 5:46:37 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Director Hornsey Liane bought $35,900 worth of shares (10,000 units at $3.59) (SEC Form 4)

    4 - Cardlytics, Inc. (0001666071) (Issuer)

    8/12/24 5:45:56 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Director Klinck John L. Jr. bought $48,860 worth of shares (14,000 units at $3.49), increasing direct ownership by 26% to 67,593 units (SEC Form 4)

    4 - Cardlytics, Inc. (0001666071) (Issuer)

    8/12/24 5:39:19 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    $CDLX
    Leadership Updates

    Live Leadership Updates

    View All

    Cardlytics Appoints Company Alumnus David Evans as Chief Financial Officer

    Cardlytics Inc. (NASDAQ:CDLX) today announced the appointment of David Evans as its new Chief Financial Officer, effective January 12, 2026. Evans is returning to Cardlytics, having previously held several executive roles including Chief Financial Officer and Chief Administrative Officer. As the returning Chief Financial Officer, Evans will oversee Cardlytics' finance, accounting, and investor relations functions as the company continues to execute against its longer-term growth vision. Evans rejoins Cardlytics after his initial tenure from 2014 to 2020, during which he helped guide the company through its earlier years of growth and a successful IPO in 2018. Evans is a seasoned executive

    12/18/25 8:10:00 AM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    TTV Capital Adds Lynne Laube and Rachel Hamilton as Venture Partners

    Co-founder and CEO of Cardlytics, Greenlight CMO to Provide Decades of Operational and Marketing Expertise to Portfolio Companies as Firm Enters 25th Year of Fintech Investing ATLANTA, April 30, 2025 /PRNewswire/ -- TTV Capital, an early-stage fintech venture capital firm, today announced that Lynne Laube and Rachel Hamilton have joined as venture partners. In these roles, Lynne and Rachel will provide strategic counsel to TTV Capital's portfolio companies based on their decades of experience scaling early-stage fintech companies. Today's news arrives as TTV Capital marks its 25th year of investing from its home base in Atlanta, the center of the fintech ecosystem. "We started investing in

    4/30/25 9:00:00 AM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    23andMe Appoints Three New Independent Directors to Board

    SUNNYVALE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (the "Company" or "23andMe"), a leading human genetics and preventive health company, today announced the appointments of Andre Fernandez, Jim Frankola, and Mark Jensen, three accomplished and experienced executives, as independent members of the Company's Board of Directors (the "Board"), effective on October 28, 2024. Each of Mr. Fernandez, Mr. Frankola, and Mr. Jensen have been appointed to serve as members of the Board's Audit Committee and Compensation Committee, with Mr. Fernandez serving as the Chair of the Audit Committee and Mr. Jensen serving as the Chair of the Compensation Committee. In additio

    10/29/24 7:30:00 AM ET
    $ANSS
    $CDLX
    $LSCC
    Computer Software: Prepackaged Software
    Technology
    Computer Software: Programming Data Processing
    Semiconductors

    $CDLX
    Financials

    Live finance-specific insights

    View All

    Cardlytics Announces Third Quarter 2025 Financial Results

    Cardlytics, Inc. (NASDAQ:CDLX), a commerce media platform, today announced financial results for the third quarter ended September 30, 2025. "In Q3, we've taken decisive action that we believe will reset our business, improve our financial health, and set ourselves on a viable path to return to growth," said Amit Gupta, CEO of Cardlytics. "We are moving forward with sharper focus and discipline, prioritizing initiatives that build on our fundamental strengths and where we believe we can win. Our mandate is clear – continue to deliver for our partners and advertisers, strengthen what differentiates us, and unlock long-term value for our shareholders." Third Quarter 2025 Financial Results

    11/5/25 4:05:00 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Cardlytics Announces Timing of Its Third Quarter 2025 Earnings Release

    Cardlytics, Inc. (NASDAQ:CDLX) today announced that its financial results for the third quarter ending September 30, 2025 will be released on November 5, 2025, after market close. Conference Call Details: When: November 5, 2025 at 5:00 pm Eastern time / 2:00 pm Pacific time Webcast: Attendees may access the live audio webcast on the Cardlytics Investor Relations website at ir.cardlytics.com, or by registering at this link. Following the call, a replay will be available on the website. Dial-in: Call participants may dial +1 800-549-8228 and use Conference ID: 18219. About Cardlytics Cardlytics (NASDAQ:CDLX) is a commerce media platform, powered by our publishers' first-party

    10/22/25 4:05:00 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Cardlytics Announces Second Quarter 2025 Financial Results

    Cardlytics, Inc. (NASDAQ:CDLX), a commerce media platform, today announced financial results for the second quarter ended June 30, 2025. "Building on the progress we've made over the past year, we are navigating headwinds by doubling down on our diversification efforts and reinforcing our unique network capabilities," said Amit Gupta, CEO of Cardlytics. "We believe our strategic shifts will position us for long-term profitable growth and enable us to deliver on the promise to our stakeholders." Second Quarter 2025 Financial Results Revenue was $63.2 million, a decrease of 9% year-over-year compared to $69.6 million in the second quarter of 2024. Billings, a non-GAAP metric, was $1

    8/6/25 4:05:00 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    $CDLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Cardlytics Inc.

    SC 13D/A - Cardlytics, Inc. (0001666071) (Subject)

    7/2/24 7:05:14 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    SEC Form SC 13D/A filed by Cardlytics Inc. (Amendment)

    SC 13D/A - Cardlytics, Inc. (0001666071) (Subject)

    3/29/24 5:05:56 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    SEC Form SC 13D/A filed by Cardlytics Inc. (Amendment)

    SC 13D/A - Cardlytics, Inc. (0001666071) (Subject)

    3/18/24 7:46:57 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology